The Blood lab has introduced new technology to improve our ability to provide a comprehensive resource for research in hemoglobinopathies.
The development of a new annexin V derivative, di-annexin, has allowed us to improve detection of PS exposing cells(Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 97:478-486, 2007).
We have introduced a novel way to augment the stem cell count in cord blood by mobilizing stem cells from human term placenta (Serikov V, Hounshell C, Larkin S, Green W, Ikeda H, Walters MC, Kuypers FA. Human term placenta as a source of hematopoietic cells. Exp Biol Med (Maywood) 234:813-823, 2009).
A novel technology allows us to analyze heterogeneous cell populations (Lee WC, Rigante S, Pisano AP, Kuypers FA. Large-scale arrays of picolitre chambers for single-cell analysis of large cell populations. Lab Chip 10:2952-2958, 2010).